Astrana Health, Inc. cash flow to debt ratio of 10.63% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Astrana Health, Inc.'s free cash flow has increased 136.58% from $44.17M last year to $104.49M, signaling increasing performance

Astrana Health, Inc.'s debt to equity ratio is 1.18, which means that the company's assets are unhealthy financed, signaling financial risk.

Astrana Health, Inc.'s debt has increased relative to shareholder equity from 0.66 last year to 1.18 today, signaling weakened financials

Astrana Health, Inc. has a net debt to EBITDA ratio of 4.79x, which exceeds the 3.00x threshold, indicating high leverage and potential financial risk

Astrana Health, Inc.'s interest coverage ratio is 1.49, which means that the company struggles to meet interest obligations, signaling financial risk.

Astrana Health, Inc.'s profit margin has decreased (50.26%) in the last year from 2.12% to 1.05%, signaling decreasing performance

Astrana Health, Inc.'s short-term assets of $863.31M exceed its short-term liabilities of $615.27M

Astrana Health, Inc.'s return on assets of 1.78% is lower than the 5.00% threshold, indicating inefficient asset utilization

Astrana Health, Inc.'s return on equity of 5.09%, is lower than 15.00%, indicating bad performance

Astrana Health, Inc.'s operating cash flow exceeds its net income, indicating high-quality earnings backed by actual cash generation

Astrana Health, Inc. had positive net income in 5 out of 5 years, indicating stable and consistent earnings

Astrana Health, Inc. has positive free cash flow, indicating the company generates cash after capital expenditures

Astrana Health, Inc. has a free cash flow yield of 5.62%, which is above the 2.00% threshold, indicating strong cash generation relative to market value

Astrana Health, Inc.'s yearly earnings has decreased 47.89% since last year from $43.15M to $22.49M, signaling decreasing performance

Astrana Health, Inc.'s yearly revenue has increased 56.39% since last year from $2.03B to $3.18B, signaling increasing performance

ROIC 4.10% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Astrana Health, Inc.'s 3-year revenue CAGR of 40.62% is positive, indicating growing revenue over the past 3 years

Astrana Health, Inc. had revenue growth in 5 out of 5 years, indicating consistent revenue performance

Astrana Health, Inc. had positive ROE in 5 out of 5 years, indicating consistent and reliable returns on equity

Astrana Health, Inc. is overvalued relative to its fair value price of 24.05 based on Discounted Cash Flow model

Astrana Health, Inc. has an earnings yield of 2.20%, which is below the 4.00% threshold, indicating the stock may be expensive relative to its earnings

Astrana Health, Inc. is overvalued relative to its fair value price of 4.42 based on EBITDA multiple model

Astrana Health, Inc. has an EV/EBITDA ratio of 18.53x, which is below the 20.00x threshold, indicating reasonable valuation relative to its operating earnings

Astrana Health, Inc. is undervalued relative to its fair value price of 55.80 based on Earnings Fair Value model

Astrana Health, Inc.'s earnings growth over the measurement period is negative; the PEG ratio is not meaningful and the check fails.

Astrana Health, Inc. has a price-to-book ratio of 3.07x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Astrana Health, Inc. has a price-to-sales ratio of 0.48x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue